Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Mar 15, 2023; 15(3): 405-424
Published online Mar 15, 2023. doi: 10.4251/wjgo.v15.i3.405
Published online Mar 15, 2023. doi: 10.4251/wjgo.v15.i3.405
Table 2 Activity of combinations of immune checkpoint inhibitors from the clinical trials
Drugs | Targets | Other treatment | Trial identifier | Patient group | n | mOS in mo | ORR, % | DCR, % | mPFS in mo | Phase | Setting |
Nivolumab + ipilimumab | PD-1; CTLA-4 | No | NCT01658878 | Advanced HCC | 50 | 22.80 | 32.0 | 54.0 | I/II | 1L | |
Durvalumab + tremelimumab | PD-L1; CTLA4 | vs Durvalumab and tremelimumab | NCT02519348 | Unresectable HCC | 75 | 18.70 | 24.0 | 45.3 | 2.17 | I/II | 2L |
Durvalumab + tremelimumab | PD-L1; CTLA4 | vs Durvalumab and sorafenib | NCT03298451 | Unresectable HCC | 393 | 16.40 | 20.1 | 60.1 | 3.78 | III | 1L |
- Citation: Luo YZ, Zhu H. Immunotherapy for advanced or recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(3): 405-424
- URL: https://www.wjgnet.com/1948-5204/full/v15/i3/405.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i3.405